Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

January 25, 2024

https://www.globenewswire.com/news-release/2024/01/25/2816773/0/en/Processa-Pharmaceuticals-Announces-Successful-Completion-of-Phase-1b-Safety-Evaluation-of-NGC-Cap-in-Patients-with-Advanced-Cancer-Resulting-in-Recommended-Phase-2-Doses.html

Next Generation Capecitabine (NGC-Cap) provides patients with 2-10 times greater exposure to its 5-FU cancer treatment metabolite than capecitabine administration

Read more at globenewswire.com

Related news for (PCSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.